Left Ventricular Impella Device Real-World Evaluation in Pediatric Patients
Key facts
- Who runs it
- Abiomed Inc.
- Where
- Atlanta, Aurora, Boston, Charleston, Chicago, Cincinnati, Dallas, Hollywood, Houston, Kansas City, Loma Linda, Los Angeles, Louisville, Memphis, Milwaukee, Nashville, New Hyde Park, New York, Palo Alto, Philadelphia, Phoenix, Pittsburgh, Salt Lake City, and Seattle, United StatesSee the 24 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 60 people, planned
- Started
- 3 Dec 2024
- Expected to end
- Dec 2027
- Type of study
- Observational
- Treatments tested
- Impella CP with SmartAssist
- Impella 5.5 with SmartAssist
- Record updated
- 17 November 2026
Who can take part
- Age
- Up to 21 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patient received a left/systemic ventricular Impella device: Impella CPSA and/or Impella 5.5
- Age < 22 years
Who cannot take part
- Age ≥ 22 years
Where in United States
- Children's Healthcare of AtlantaAtlanta, United States
- Children's Hospital ColoradoAurora, United States
- Boston Children's HospitalBoston, United States
- MUSC Children's HealthCharleston, United States
- Lurie Children's Hospital of ChicagoChicago, United States
- Cincinnati Children's Hospital Medical CenterCincinnati, United States
- Children's Medical Center DallasDallas, United States
- Joe DiMaggio Children's HospitalHollywood, United States
- Texas Children's HospitalHouston, United States
- Children's Mercy HospitalKansas City, United States
- Loma Linda University Children's HospitalLoma Linda, United States
- Children's Hospital Los AngelesLos Angeles, United States
- Norton Children's HospitalLouisville, United States
- Le Bonheur Children's HospitalMemphis, United States
- Children's Hospital of WisconsinMilwaukee, United States
- Monroe Carell Jr. Children's Hospital at VanderbiltNashville, United States
- Cohen Children's Medical CenterNew Hyde Park, United States
- New York -Presbyterian Morgan Stanley Children's HospitalNew York, United States
- Lucile Packard Children's Hospital - StanfordPalo Alto, United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
- Phoenix Children s HospitalPhoenix, United States
- UPMC Children's Hospital of PittsburghPittsburgh, United States
- Primary Children's HospitalSalt Lake City, United States
- Seattle Children's HospitalSeattle, United States
About the trial
What the trial wants to find out
This post-approval study will evaluate the real-world safety and effectiveness of the Impella CP with SmartAssist and Impella 5.5 with SmartAssist heart pumps in pediatric patients with cardiogenic shock or severe heart failure requiring temporary mechanical circulatory support.
Read full original descriptionShow less
The study will collect data from children and young adults younger than 22 years of age who receive an Impella device as part of their routine clinical care at hospitals participating in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry.
The primary objective is to assess survival at the time the Impella device is removed. Information collected during the patient's hospitalization, including clinical outcomes and adverse events, will be used to further evaluate the performance of these commercially approved devices in the pediatric population.
The group in the trial
- Pediatric Patients Receiving Impella Support
Pediatric patients younger than 22 years of age who receive a commercially approved left ventricular Impella device (Impella CP with SmartAssist and/or Impella 5.5 with SmartAssist) as part of routine clinical care and are enrolled through the ACTION (Advanced Cardiac Therapies Improving Outcomes Network) registry.
Treatment: Impella CP with SmartAssist and Impella 5.5 with SmartAssist
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 November 2026